About: Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Sector: Healthcare
Industry: Biotechnology
Latest price: $11.88 (+12.39%)
ABSI NASDAQ Absci Corp
Absci Corp share price
Atividade de preço de ABSI
Último preço
$ 11,880
Variação (24h)
1,31 USD (12,39%)
Volume
5.79M
Volume (média 4 sem.)
-
Abertura
$ 10,55
Variação do dia
$ 10,43 - $ 11,88
Fechamento anterior
$ 10,57
Último negócio
28 Oct, 8:28 pm GMT+0
Atrasado
28 Oct, 8:28 pm GMT+0
ABSI price performance
Atrasado
28 Oct, 8:28 pm GMT+0
quote.marketSignals